Sclerotherapy with 3% polidocanol foam to treat second-degree haemorrhoidal disease: Three-year follow-up of a multicentre, single arm, IDEAL phase 2b trial.
Gaetano GalloArcangelo PicciarielloRenato PietrolettiEugenio NovelliAlessandro SturialeRoberta TutinoRita LaforgiaElisabetta MoggiaMauro PozzoMaurizio RoveroniVincenzo BiancoAlberto Realis LucAntonio GiulianiElia DiacoGabriele NaldiniMario TrompettoRoberto PerinottiVito D'AndreaPierluigi LobascioPublished in: Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland (2022)
Sclerotherapy with 3% polidocanol foam is gradually establishing itself in the treatment of bleeding HD due to its repeatability, safety, convenience in terms of direct and indirect costs with the absence of discomfort for the patient as well as AEs rather than an excellent overall success rate.